Effects of tACS Combined With CCT for Patients With MCI
NCT04135742, Not applicable, Unknown, Shanghai Mental Health Center
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Effects of tACS Combined With CCT for Patients With MCI | ClinicalTrials.gov |
| NCT number | NCT04135742 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 195 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Shanghai Mental Health Center | ClinicalTrials.gov |
| Conditions | Mild Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Transcranial Alternating Current Stimulation, Cognitive Training | ClinicalTrials.gov |
| First posted | 2019-10-23 | ClinicalTrials.gov |
| Last updated | 2022-05-06 | ClinicalTrials.gov |
Registered outcomes 11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from baseline RBANS, Color Word Stroop Test (CWST),Visual Reasoning and Trails Making Task. | up to 3 months(end of the intervention) | Global cognition will be assessed by the Repeatable Battery for the Assessment of Neuropsychological Status Total Score (RBANS).CWST mainly can examine the executive function. Visual Reasoning will be assessed by the Cambridge Mental Disorders of the Elderly Examination Visual Reasoning Test.Executive function will be assessed by Trails Making Task. | ClinicalTrials.gov |
| Primary | Neuroimage change from baseline Magnetic Resonance Imaging (MRI) | up to 3 months(end of the intervention) | Including T1, resting state functional MRI, task based functional MRI and Diffusion Tensor Imaging(DTI) | ClinicalTrials.gov |
| Primary | changes in Gamma oscillation intensity (40-80 Hz) over DLPFC | up to 3 months(end of the intervention) | measured by electroencephalogram (EEG) | ClinicalTrials.gov |
| Secondary | Changes from baseline RBANS | 3 months after the end of the intervention,6 months after the end of the intervention and 12 month after the end of the intervention | Global cognition will be assessed by the Repeatable Battery for the Assessment of Neuropsychological Status Total Score (RBANS). | ClinicalTrials.gov |
| Secondary | Changes from baseline Color Word Stroop Test (CWST) | 3 months after the end of the intervention,6 months after the end of the intervention and 12 month after the end of the intervention | CWST mainly can examine the executive function. There are age-, sex-, and educational year-stratified norms; individuals' z-score can be calculated. | ClinicalTrials.gov |
| Secondary | Changes from baseline Visual Reasoning | 3 months after the end of the intervention,6 months after the end of the intervention and 12 month after the end of the intervention | Visual Reasoning will be assessed by the Cambridge Mental Disorders of the Elderly Examination Visual Reasoning Test. | ClinicalTrials.gov |
| Secondary | Changes from baseline Trails Making Task | 3 months after the end of the intervention,6 months after the end of the intervention and 12 month after the end of the intervention | Executive function will be assessed by Trails Making Task. | ClinicalTrials.gov |
| Secondary | Changes from baseline Geriatric Depression Scale (GDS) | up to 3 months(end of the intervention),3 months after the end of the intervention,6 months after the end of the intervention and 12 month after the end of the intervention | The Geriatric Depression Scale will be used to measure neuropsychiatric symptoms. It ranges from 0 to 30, and higher value represents a worse outcome. | ClinicalTrials.gov |
| Secondary | Changes from baseline in Geriatric Anxiety Inventory (GAI) | up to 3 months(end of the intervention),3 months after the end of the intervention,6 months after the end of the intervention and 12 month after the end of the intervention | Geriatric Anxiety Inventory (GAI) will be used to measure neuropsychiatric symptoms. | ClinicalTrials.gov |
| Secondary | Neuroimage changes from baseline Magnetic Resonance Imaging (MRI) | 6 months after the end of the intervention and 12 month after the end of the intervention | Including T1, resting state functional MRI, task based functional MRI and Diffusion Tensor Imaging(DTI) | ClinicalTrials.gov |
| Secondary | Side-effects of tACS | At each stimulation session,up to 3 months. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)